USPTO Patent Grant for CAH Treatment Compound
Summary
The USPTO has granted patent US12582634B2 to Neurocrine Biosciences, Inc. for a compound and synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent covers specific chemical structures and their preparation, aiming to provide new therapeutic options for this condition.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12582634B2, granting Neurocrine Biosciences, Inc. exclusive rights to a specific compound and its synthetic methods for treating congenital adrenal hyperplasia (CAH). The patent details the chemical structure of the compound, identified as 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine, along with its pharmaceutically acceptable salts and crystalline forms.
This patent grant signifies a new intellectual property asset for Neurocrine Biosciences, potentially impacting future drug development and market exclusivity in the therapeutic area of CAH. While this is a patent grant and not a regulatory rule with compliance deadlines, it is relevant for pharmaceutical companies operating in the endocrinology and rare disease space. Compliance officers should note this as a development in the competitive landscape for CAH treatments.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine
Grant US12582634B2 Kind: B2 Mar 24, 2026
Assignee
Neurocrine Biosciences, Inc.
Inventors
Andrew Becker, Scott Stirn, Joel Radisson, Christina Marie Costa
Abstract
The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).
CPC Classifications
A61K 31/426 A61K 9/0095 A61K 9/107 A61K 9/28 A61K 9/4833 A61K 45/06 A61K 47/10 A61K 47/14 A61K 47/22 A61K 47/26 A61K 47/32 A61K 31/573 A61K 2300/00 A61K 9/0053 A61K 9/1635 A61K 9/1652 C07D 277/42 C07B 2200/13 A61P 5/00 C07C 209/52 C07C 249/02 C07C 259/06 C07C 211/29 C07C 251/24 G01N 33/74
Filing Date
2020-06-10
Application No.
17782617
Claims
101
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.